
American-Israeli startup PhaseV is on a mission to overcome one of the most significant challenges of drug development: the clinical trial phase, the longest and most expensive part of the process.
A recent Deloitte report reveals that, on average, a single new drug takes $2.3 billion and seven years to develop.